Feedback / Questions
PMC-403 - PharmAbcine
https://www.prnewswire.com/news-releases/pharmabcine-announces-safety-approval-for-4mg-single-dose-cohort-in-phase-1-clinical-trial-of-pmc-403-for-neovascular-age-related-macular-degeneration-302275767.html
Oct 14, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next